October 22, 2017 10:25 AM ET


Company Overview of Ardelyx, Inc.

Key Executives for Ardelyx, Inc.

NameBoard RelationshipsTitleAge
Michael G. Raab 30 RelationshipsChief Executive Officer, President and Director52
Mark E. Kaufmann MBA5 RelationshipsCFO & Treasurer49
Reginald Seeto M.D., MBBS13 RelationshipsChief Operating Officer and Executive Vice President45
Robert C. Blanks MS, RAC No RelationshipsSenior Vice President of Regulatory Affairs and Quality Assurance--
Jeremy S. Caldwell Ph.D.5 RelationshipsChief Scientific Officer and Executive Vice President48
View More Key Executives

Ardelyx, Inc. Board Members*

NameBoard RelationshipsPrimary CompanyAge
David M. Mott 206 RelationshipsMersana Therapeutics, Inc.51
Michael G. Raab 30 RelationshipsArdelyx, Inc.52
Richard J. Rodgers 23 RelationshipsArdelyx, Inc.50
Gordon Ringold Ph.D. 55 RelationshipsAlavita Pharmaceuticals Inc.66
Annalisa Mary Jenkins MBBS, FRCP 91 RelationshipsDimension Therapeutics, Inc.52
View All Board Members

Ardelyx, Inc. Executive Committees*

Committee NameChairpersonBoard RelationshipsMembers
Audit Committee Richard J. Rodgers23 Relationships3 Executives
Compensation Committee David M. Mott206 Relationships4 Executives
Nominating Committee Ph.D.Gordon Ringold55 Relationships3 Executives
Corporate Governance Committee Ph.D.Gordon Ringold55 Relationships3 Executives
View Committee Details
*Data is at least as current as the most recent Definitive Proxy.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup


  Industry Range
Not meaningful
Total Short Term Compensation$5.2M
Not meaningful
Total Value of Options$520.0K
Compensation as of Fiscal Year 2016
Ardelyx, Inc. CEO Compensation
Industry Average


Verseon Corporation Appoints Robert W. Karr as Non-Executive Class II Director
October 20, 2017 6:00 AM ET
Neurocrine Biosciences, Inc. Announces Management Changes
October 19, 2017 9:26 PM ET
AveXis, Inc. Announces Management Changes
October 19, 2017 8:58 PM ET
Peregrine Pharmaceuticals, Inc. and Avid Bioservices, Inc. Appoint Mark R. Bamforth as an Independent Member of the Board of Directors
October 19, 2017 12:05 PM ET
Cellect Biotechnology Ltd. Announces Executive Changes
October 19, 2017 11:05 AM ET

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Ardelyx, Inc., please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.